Neil Kumar - 01 Jul 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: BBIO
Reported as of: 01 Jul 2025
Net transaction value: -$3,410,450
SEC form: 4
Accepted by SEC: 03 Jul 2025, 16:30:19 UTC
Prior SEC filing: 20 May 2025
Next SEC filing: 11 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Neil Kumar

Key filing fact

Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 03 Jul 2025.

Key facts

This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
6 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Jul 2025, 16:30.

Change

Previous filing in this sequence was filed on 20 May 2025.
Current net transaction value: -$3,410,450.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742485 Primary reporting owner

Kumar Neil

Relationship: Chief Executive Officer, Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Neil Kumar
Signature date: 02 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Sale

Transaction value: $777,777
Shares: -18,300
Change %: -0.38%
Price: $42.50
Shares after: 4,780,147
Date: 01 Jul 2025
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F2, F3

BBIO transaction

Common Stock

Sale

Transaction value: $72,903
Shares: -1,700
Change %: -0.04%
Price: $42.88
Shares after: 4,778,447
Date: 01 Jul 2025
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F4

BBIO transaction

Common Stock

Sale

Transaction value: $854,536
Shares: -20,000
Change %: -0.42%
Price: $42.73
Shares after: 4,758,447
Date: 02 Jul 2025
Ownership: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F5

BBIO transaction

Common Stock

Sale

Transaction value: $782,092
Shares: -18,400
Change %: -1.8%
Price: $42.50
Shares after: 977,286
Date: 01 Jul 2025
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F6

BBIO transaction

Common Stock

Sale

Transaction value: $68,628
Shares: -1,600
Change %: -0.16%
Price: $42.89
Shares after: 975,686
Date: 01 Jul 2025
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F7

BBIO transaction

Common Stock

Sale

Transaction value: $854,514
Shares: -20,000
Change %: -2%
Price: $42.73
Shares after: 955,686
Date: 02 Jul 2025
Ownership: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.
Footnotes: F1, F3, F8

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 217,404
Date: 01 Jul 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 8 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.

Footnote F2

Represents the weighted average sale price of the shares sold from $41.80 to $42.79 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F3

The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

Footnote F4

Represents the weighted average sale price of the shares sold from $42.81 to $42.96 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F5

Represents the weighted average sale price of the shares sold from $42.145 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F6

Represents the weighted average sale price of the shares sold from $41.81 to $42.80 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F7

Represents the weighted average sale price of the shares sold from $42.81 to $42.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Footnote F8

Represents the weighted average sale price of the shares sold from $42.22 to $43.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.